Cancers of the Oral Mucosa Differential Diagnoses

  • Author: Crispian Scully, MD, PhD, MDS, CBE, MRCS, FDSRCS, FDSRCPS, FFDRCSI, FDSRCSE, FRCPath, FMedSci, FHEA, FUCL, DSc, DChD, DMed(HC), Dr(HC), ; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Apr 20, 2012
 
 

Differential Diagnoses

Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Crispian Scully, MD, PhD, MDS, CBE, MRCS, FDSRCS, FDSRCPS, FFDRCSI, FDSRCSE, FRCPath, FMedSci, FHEA, FUCL, DSc, DChD, DMed(HC), Dr(HC),  Professor of Oral Medicine, Bristol University; Co-Director of World Health Organization Collaborating Centre for Oral Health-General Health; Emeritus Professor of Oral Medicine and Special Care Dentistry, University College London; Professor, Oral Medicine, Pathology, and Microbiology, University of London; Visiting Professor at Universities of Athens,Edinburgh, Granada, Helsinki and Plymouth

Crispian Scully, MD, PhD, MDS, CBE, MRCS, FDSRCS, FDSRCPS, FFDRCSI, FDSRCSE, FRCPath, FMedSci, FHEA, FUCL, DSc, DChD, DMed(HC), Dr(HC), is a member of the following medical societies: Academy of Medical Science, British Society for Oral Medicine, European Association for Oral Medicine, International Academy of Oral Oncology, International Association for Dental Research, and International Association for Oral and Maxillofacial Pathology

Disclosure: Nothing to disclose.

Specialty Editor Board

Kelly M Cordoro, MD  Assistant Professor of Clinical Dermatology and Pediatrics, Department of Dermatology, University of California, San Francisco School of Medicine

Kelly M Cordoro, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Association of Professors of Dermatology, Dermatology Foundation, Medical Society of Virginia, National Psoriasis Foundation, Society for Pediatric Dermatology, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

John G Albertini, MD  Consulting Staff, Dermatologic Surgery, The Skin Surgery Center; Program Director, ACGME Accredited Fellowship in Procedural Dermatology

John G Albertini, MD is a member of the following medical societies: American Academy of Dermatology and American College of Mohs Micrographic Surgery and Cutaneous Oncology

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Nagler R, Dayan D. The dual role of saliva in oral carcinogenesis. Oncology. 2006;71(1-2):10-7. [Medline].

  2. Tomar SL, Loree M, Logan H. Racial differences in oral and pharyngeal cancer treatment and survival in Florida. Cancer Causes Control. Aug 2004;15(6):601-9. [Medline].

  3. Scully C, Bedi R. Ethnicity and oral cancer. Lancet Oncol. Sep 2000;1(1):37-42. [Medline].

  4. Campisi G, Panzarella V, Giuliani M, Lajolo C, Di Fede O, Falaschini S, et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions (review). Int J Oncol. Apr 2007;30(4):813-23. [Medline].

  5. Petti S, Scully C. Oral cancer: the association between nation-based alcohol-drinking profiles and oral cancer mortality. Oral Oncol. Sep 2005;41(8):828-34. [Medline].

  6. Su CC, Yang HF, Huang SJ, Lian IeB. Distinctive features of oral cancer in Changhua County: high incidence, buccal mucosa preponderance, and a close relation to betel quid chewing habit. J Formos Med Assoc. Mar 2007;106(3):225-33. [Medline].

  7. Rodu B, Jansson C. Smokeless tobacco and oral cancer: a review of the risks and determinants. Crit Rev Oral Biol Med. 2004;15(5):252-63. [Medline].

  8. Warnakulasuriya S. Smokeless tobacco and oral cancer. Oral Dis. Jan 2004;10(1):1-4. [Medline].

  9. Rosenquist K, Wennerberg J, Schildt EB, Bladström A, Göran Hansson B, Andersson G. Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol. Dec 2005;125(12):1327-36. [Medline].

  10. Scully C. Oral squamous cell carcinoma; from an hypothesis about a virus, to concern about possible sexual transmission. Oral Oncol. Apr 2002;38(3):227-34. [Medline].

  11. Mallery SR, Stoner GD, Larsen PE, Fields HW, Rodrigo KA, Schwartz SJ, et al. Formulation and in-vitro and in-vivo evaluation of a mucoadhesive gel containing freeze dried black raspberries: implications for oral cancer chemoprevention. Pharm Res. Apr 2007;24(4):728-37. [Medline].

  12. Boyle P, Maisoneuve P, Andreoni B, et al. Prevention of upper gastrointestinal tract cancer. In: Recent Advances in the Treatment and Biology of Solid Tumours. Oxford, England: Medicine Foundation; 1997:27-33.

  13. Macha MA, Matta A, Kaur J, et al. Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck. Apr 2011;33(4):482-9. [Medline].

  14. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. Jul 1 2001;19(13):3234-43. [Medline].

  15. Kies MS, Arquette M, Nabell L, et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody, cetuximab (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SSCHN) refractory to cisplatin. Proc Am Soc Clin Oncol. 2002;21:232a.

  16. Baselga J, Trigo JM, Bourhis J, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol. 2002;21:226a.

  17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. Feb 9 2006;354(6):567-78. [Medline].

  18. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. Aug 20 2005;23(24):5578-87. [Medline].

  19. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. Aug 20 2005;23(24):5568-77. [Medline].

  20. Vermorken JB, Mesia R, Vega-Villegas ME, et al. Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Am Soc Clin Onco lProc. 2006;Abstract 5537:24:289s.

  21. Kies MS, Garden AS, Holsinger C, et al. Induction chemotherapy with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 2006;Abstract 5520.:24:285s.

  22. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. Dec 1 2005;23(34):8646-54. [Medline].

  23. Hamakawa H, Nakashiro K, Sumida T, et al. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck. Jun 2008;30(6):800-9. [Medline].

  24. Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. Jun 2011;47(6):441-8. [Medline].

  25. Calabrese L, Tradati N, Nickolas TL, Giugliano G, Zurrida S, Scully C, et al. Cancer screening in otorhinolaryngology. Oral Oncol. Jan 1998;34(1):1-4. [Medline].

  26. La Vecchia C. Mouthwash and oral cancer risk. Oral Oncology. March 2009;45(3):198-200.

  27. Lavelle CL, Scully C. Criteria to rationalize population screening to control oral cancer. Oral Oncol. Jan 2005;41(1):11-6. [Medline].

  28. McCullough MJ, Farah CS. The role of alcohol in oral carcinogenesis withparticular reference to alcohol-containing mouthwashes. Aust Dent J. Dec 2008;53(4):302-305.

  29. Schantz SP, Yu GP. Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg. Mar 2002;128(3):268-74. [Medline].

  30. Scheifele C, Reichart PA, Hippler-Benscheidt M, Neuhaus P, Neuhaus R. Incidence of oral, pharyngeal, and laryngeal squamous cell carcinomas among 1515 patients after liver transplantation. Oral Oncol. Aug 2005;41(7):670-6. [Medline].

  31. Sciubba JJ. Oral cancer. The importance of early diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):239-51. [Medline].

  32. Sciubba JJ. Oral leukoplakia. Crit Rev Oral Biol Med. 1995;6(2):147-60. [Medline].

  33. Scully C. Chemoprevention in oral cancer. J Manag Care. 1997;1:116-22.

  34. Scully C. Oral precancer: preventive and medical approaches to management. Eur J Cancer B Oral Oncol. Jan 1995;31B(1):16-26. [Medline].

  35. Scully C, Cawson RA. Potentially malignant oral lesions. J Epidemiol Biostat. 1996;1:3-12.

  36. Scully C, Epstein JB. Oral health care for the cancer patient. Eur J Cancer B Oral Oncol. Sep 1996;32B(5):281-92. [Medline].

  37. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. May 2000;36(3):256-63. [Medline].

  38. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. Oral Oncol. Jul 2000;36(4):311-27. [Medline].

  39. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinico-pathological applications. Oral Oncol. Sep 2000;36(5):404-13. [Medline].

  40. Scully C, Sudbo J, Speight PM. Progress in determining the malignant potential of oral lesions. J Oral Pathol Med. May 2003;32(5):251-6. [Medline].

  41. Scully C, Ward-Booth RP. Detection and treatment of early cancers of the oral cavity. Crit Rev Oncol Hematol. Nov 1995;21(1-3):63-75. [Medline].

  42. Singh N, Scully C, Joyston-Bechal S. Oral complications of cancer therapies: prevention and management. Clin Oncol (R Coll Radiol). 1996;8(1):15-24. [Medline].

  43. Sturgis EM. A review of social and behavioral efforts at oral cancer preventions in India. Head Neck. Nov 2004;26(11):937-44. [Medline].

  44. Tradati N, Grigolat R, Calabrese L, Costa L, Giugliano G, Morelli F, et al. Oral leukoplakias: to treat or not?. Oral Oncol. Sep 1997;33(5):317-21. [Medline].

  45. Tumino R, Vicario G. Head and neck cancers: oral cavity, pharynx, and larynx. Epidemiol Prev. Mar-Apr 2004;28(2 Suppl):28-33. [Medline].

  46. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. Dec 1999;8(12):1071-8. [Medline].

 
Previous
Next
 
Oral squamous cell carcinoma in the most common intraoral site manifesting as a chronic, indurated ulcer.
Early oral squamous cell carcinoma in the buccal mucosa arising from a chronic candidal leukoplakia in a person who smokes heavily. The lesion was a painless, chronic indurated lump.
Cancer developing on the gingiva.
Cervical lymph node metastasis from oral cancer.
Table 1. Targeted therapies for oral cancer and oral adverse effects
TherapiesExamplesAdverse effects
EGFR inhibitors (FDA approved)CetuximabUlcers
EGFR inhibitorsPanitumumab, erlotinib in combination with gemcitabineUlcers
mTOR inhibitorsDeforolimus, rapamycin (sirolimus) and temsirolimusUlcers
Tyrosine kinase inhibitors (TKIs) of platelet-derived growth factor (PDGF)ImatinibUlcers, dysgeusia
TKIs of PDGF and vascular endothelial growth factor (VEGF)SunitinibUlcers, dry mouth, dysgeusia
Raf multi-kinase inhibitorsSorafenibDysgeusia
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.